These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 1666746)

  • 21. Comparison of the transient equilibrium and continuous infusion method for quantitative PET analysis of [11C]raclopride binding.
    Ito H; Hietala J; Blomqvist G; Halldin C; Farde L
    J Cereb Blood Flow Metab; 1998 Sep; 18(9):941-50. PubMed ID: 9740097
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [11C]raclopride-PET studies of the Huntington's disease rate of progression: relevance of the trinucleotide repeat length.
    Antonini A; Leenders KL; Eidelberg D
    Ann Neurol; 1998 Feb; 43(2):253-5. PubMed ID: 9485067
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography.
    Brooks DJ; Ibanez V; Sawle GV; Playford ED; Quinn N; Mathias CJ; Lees AJ; Marsden CD; Bannister R; Frackowiak RS
    Ann Neurol; 1992 Feb; 31(2):184-92. PubMed ID: 1575457
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Brain dopamine receptors in schizophrenia: PET problems.
    Seeman P
    Arch Gen Psychiatry; 1988 Jun; 45(6):598-600. PubMed ID: 3259865
    [No Abstract]   [Full Text] [Related]  

  • 25. Gpp(NH)p stimulates [3H]raclopride binding to homogenates from human putamen and accumbens.
    Hall H; Halldin C; Sedvall G
    Neurosci Lett; 1992 Feb; 136(1):79-82. PubMed ID: 1635671
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The current status of PET scanning with respect to schizophrenia.
    Sedvall G
    Neuropsychopharmacology; 1992 Aug; 7(1):41-54. PubMed ID: 1388021
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Kinetic modeling of [11C]raclopride: combined PET-microdialysis studies.
    Endres CJ; Kolachana BS; Saunders RC; Su T; Weinberger D; Breier A; Eckelman WC; Carson RE
    J Cereb Blood Flow Metab; 1997 Sep; 17(9):932-42. PubMed ID: 9307606
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quantitation of carbon-11-labeled raclopride in rat striatum using positron emission tomography.
    Hume SP; Myers R; Bloomfield PM; Opacka-Juffry J; Cremer JE; Ahier RG; Luthra SK; Brooks DJ; Lammertsma AA
    Synapse; 1992 Sep; 12(1):47-54. PubMed ID: 1411963
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The potential of positron-emission tomography for pharmacokinetic and pharmacodynamic studies of neuroleptics.
    Farde L; Wiesel FA; Nilsson L; Sedvall G
    Psychopharmacol Ser; 1989; 7():32-9. PubMed ID: 2574454
    [No Abstract]   [Full Text] [Related]  

  • 30. Decrease in human striatal dopamine D2 receptor density with age: a PET study with [11C]raclopride.
    Rinne JO; Hietala J; Ruotsalainen U; Säkö E; Laihinen A; Någren K; Lehikoinen P; Oikonen V; Syvälahti E
    J Cereb Blood Flow Metab; 1993 Mar; 13(2):310-4. PubMed ID: 8436624
    [TBL] [Abstract][Full Text] [Related]  

  • 31. D4 receptors and schizophrenia.
    Strange PG; Vile JM
    J Neurochem; 1995 Nov; 65(5):2381-3. PubMed ID: 7595530
    [No Abstract]   [Full Text] [Related]  

  • 32. Quantification of [11C]FLB 457 binding to extrastriatal dopamine receptors in the human brain.
    Olsson H; Halldin C; Swahn CG; Farde L
    J Cereb Blood Flow Metab; 1999 Oct; 19(10):1164-73. PubMed ID: 10532641
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Distinct binding patterns of [3H]raclopride and [3H]spiperone at dopamine D2 receptors in vivo in rat brain. Implications for pet studies.
    Bischoff S; Gunst F
    J Recept Signal Transduct Res; 1997; 17(1-3):419-31. PubMed ID: 9029505
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Distribution of dopamine D1 and D2 receptors in rabbit cortical areas, hippocampus, and neostriatum in relation to dopamine contents.
    Dewar KM; Reader TA
    Synapse; 1989; 4(4):378-86. PubMed ID: 2532424
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of endogenous dopamine on extrastriatal [¹¹C]FLB 457 binding measured by PET.
    Okauchi T; Suhara T; Maeda J; Kawabe K; Obayashi S; Suzuki K
    Synapse; 2001 Aug; 41(2):87-95. PubMed ID: 11400175
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PET demonstrates different behaviour of striatal dopamine D-1 and D-2 receptors in early Parkinson's disease.
    Rinne JO; Laihinen A; Någren K; Bergman J; Solin O; Haaparanta M; Ruotsalainen U; Rinne UK
    J Neurosci Res; 1990 Dec; 27(4):494-9. PubMed ID: 1981915
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Imaging of dopamine receptors using PET and SPECT.
    Hall H; Farde L; Halldin C; Högberg T; Larsson S; Sedvall G
    Neurochem Int; 1992 Mar; 20 Suppl():329S-333S. PubMed ID: 1365450
    [No Abstract]   [Full Text] [Related]  

  • 38. Maps of receptor binding parameters in the human brain--a kinetic analysis of PET measurements.
    Blomqvist G; Pauli S; Farde L; Eriksson L; Persson A; Halldin C
    Eur J Nucl Med; 1990; 16(4-6):257-65. PubMed ID: 2112470
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PET studies of dopamine receptors in relation to antipsychotic drug treatment.
    Farde L; Nordström AL; Halldin C; Wiesel FA; Sedvall G
    Clin Neuropharmacol; 1992; 15 Suppl 1 Pt A():468A-469A. PubMed ID: 1354052
    [No Abstract]   [Full Text] [Related]  

  • 40. Radiochemical synthesis of [18F]fluororaclopride.
    Kiesewetter DO; Brücke T; Finn RD
    Int J Rad Appl Instrum A; 1989; 40(6):455-60. PubMed ID: 2551844
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.